| Biological Analysis of MABs in NHL in a Translational Prospective Observational Study Within Italian Clinical Practice (NCT07767799) | Fondazione Italiana Linfomi - ETS | 2026-10-01 |
| Neurocognitive Assessment in Long-Term Survivors of Lymphoma (NCT07652476) | Fondazione Italiana Linfomi - ETS | 2026-09-01 |
| Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy (NCT07453095) | Fondazione Italiana Linfomi - ETS | 2026-06-05 |
| Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment (NCT07476105) | Fondazione Italiana Linfomi - ETS | 2026-05-01 |
| BV-CHP Real-life and Biological Evidences in Patients With sALCL (NCT07467317) | Fondazione Italiana Linfomi - ETS | 2026-05-01 |
| Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy (NCT07463781) | Fondazione Italiana Linfomi - ETS | 2026-05-01 |
| PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma (NCT07256158) | Fondazione Italiana Linfomi - ETS | 2026-03-01 |
| PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma (NCT07207785) | Fondazione Italiana Linfomi - ETS | 2026-02-01 |
| Long-term Assessment of Chlormethine Gel in Mycosis Fungoides (NCT07046663) | Fondazione Italiana Linfomi - ETS | 2025-09-01 |
| Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma (NCT06588205) | Fondazione Italiana Linfomi - ETS | 2025-05-05 |
| A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL) (NCT06835530) | Fondazione Italiana Linfomi - ETS | 2025-04-09 |
| Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma (NCT06588868) | Fondazione Italiana Linfomi - ETS | 2025-02-27 |
| Study on Plasmablastic Lymphoma Patients (NCT06781359) | Fondazione Italiana Linfomi - ETS | 2025-02-14 |
| Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval. (NCT06441214) | Fondazione Italiana Linfomi - ETS | 2024-12-13 |
| PTLD: Multicentric Retrospective Study (NCT06422715) | Fondazione Italiana Linfomi - ETS | 2024-10-30 |
| Primary Cardiac Lymphoma: Italian Multicenter Experience (NCT05819528) | Fondazione Italiana Linfomi - ETS | 2024-10-02 |
| Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma (NCT06113081) | Fondazione Italiana Linfomi - ETS | 2024-06-06 |
| Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy (NCT05977673) | Fondazione Italiana Linfomi - ETS | 2024-05-23 |
| Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance (NCT06070961) | Fondazione Italiana Linfomi - ETS | 2024-05-07 |
| SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project (NCT06156774) | Fondazione Italiana Linfomi - ETS | 2024-04-18 |
| Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors (NCT05934084) | Fondazione Italiana Linfomi - ETS | 2024-02-26 |
| R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma (NCT05966233) | Fondazione Italiana Linfomi - ETS | 2024-01-01 |
| A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice (NCT06008691) | Fondazione Italiana Linfomi - ETS | 2023-12-27 |
| Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi (NCT05929222) | Fondazione Italiana Linfomi - ETS | 2023-12-14 |
| Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial (NCT05816850) | Fondazione Italiana Linfomi - ETS | 2023-09-19 |
| Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients (NCT05300282) | Fondazione Italiana Linfomi - ETS | 2023-02-27 |
| Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study. (NCT04882475) | Fondazione Italiana Linfomi - ETS | 2023-02-08 |
| Quality Of Life On Elderly Patients With Low Grade Non-Hodgkin Lymphoma (NCT05524298) | Fondazione Italiana Linfomi - ETS | 2022-12-07 |
| Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. (NCT04915248) | Fondazione Italiana Linfomi - ETS | 2022-07-11 |
| Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. (NCT05249959) | Fondazione Italiana Linfomi - ETS | 2022-03-21 |
| Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma (NCT05058404) | Fondazione Italiana Linfomi - ETS | 2021-12-01 |
| Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy (NCT04442412) | Fondazione Italiana Linfomi - ETS | 2021-03-23 |
| The Role of 18F-FDG-PET for Staging and Prognostication (NCT04600804) | Fondazione Italiana Linfomi - ETS | 2020-10-30 |
| Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH (NCT04251065) | Fondazione Italiana Linfomi - ETS | 2020-09-03 |
| Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma (NCT04433182) | Fondazione Italiana Linfomi - ETS | 2020-08-18 |
| Circulating Tumor DNA Genotyping for Biological Monitoring of Patients Treated in the FIL-Rouge Clinical Trial (NCT05066555) | Fondazione Italiana Linfomi - ETS | 2020-04-08 |
| Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma (NCT03890289) | Fondazione Italiana Linfomi - ETS | 2019-10-18 |
| Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study (NCT05162170) | Fondazione Italiana Linfomi - ETS | 2019-10-02 |
| Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL (NCT03891355) | Fondazione Italiana Linfomi - ETS | 2019-09-30 |
| Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance (NCT03731234) | Fondazione Italiana Linfomi - ETS | 2019-07-02 |
| Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma (NCT03552692) | Fondazione Italiana Linfomi - ETS | 2018-09-25 |
| Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL (NCT03567876) | Fondazione Italiana Linfomi - ETS | 2018-09-03 |
| Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS (NCT03521596) | Fondazione Italiana Linfomi - ETS | 2018-08-28 |
| Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas (NCT03161054) | Fondazione Italiana Linfomi - ETS | 2017-09-12 |